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Resolution of Severe Macular Edema in Adult Coats’ Disease 
with Intravitreal Triamcinolone and Bevacizumab Injection
Jong-Hwa Jun, MD, Yu-Cheol Kim, MD, Kwang-Soo Kim, MD
Department of Ophthalmology, School of Medicine, Dongsan Medical Center, Keimyung University, Daegu, Korea 
A 47 year old male patient visited our hospital with the chief complaint of deterioration of the visual acuity 
in the left eye. The fundus examination revealed thick hard exudates, multiple aneurysms and 
telangiectasias of the retinal vessels in the posterior pole. Fluorescein angiography demonstrated massive 
leakage over an area of the aneurysms. Optical coherence tomography (Stratus OCT; Zeiss-Humphrey, 
Dubin, CA) revealed diffuse and marked thickening of the retina. Laser photocoagulation was performed 
under the diagnosis of Coats’ disease. However, the treatment could not be performed satisfactorily. On the 
first and 6th weeks, an intravitreal injection of bevacizumab and triamcinolone acetonide was administered, 
and laser photocoagulation was again attempted. The effectiveness of eachagent on retinal edema was 
evaluated at the follow-up performed at 1, 2, 5, 7, 10 weeks and 6 months after the injection. At one week 
after the intravitreal bevacizumab injection, there was no improvement. An intravitreal injection of 
triamcinolone acetonide was performed 6 weeks after the initial diagnosis,which resulted in a reduction in 
the thickness of the macular edema. Therefore, laser photocoagulation was performed sufficiently on 
telangiectasias. The follow-up at 6 months showed a relative increase in the macular edema, but there was 
reduced leakage from the telangiectasias compared with the previous angiograph.
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Coats’ disease typically induces idiopathic retinal telan- 
giectasias in all components of the retinal vasculature. In 
addition, it induces significant lipid deposition due to the 
non-perfusion of thecapillary blood vessels, aneurysm 
formation, and subretinal exudation. Adult cases of Coats’ 
disease are often asymptomatic, or the visual acuity at the 
initial diagnosis is better than in pediatric patients. 
Leukocoria is absent at the time of diagnosis, and the extent 
of exudation and retinal detachment tends to be mild.
1 
Treatment is performed according to, the Shields 
classification.
2 The occlusion of the dilated blood vessels is 
treated by cryotherapy and laser photocoagulation for stage 
1–3A. Surgical retinal reattachment is performed for most 
cases of stage 3B. Enucleation is indicated for stage 4 
patients. In this adult Coats’ disease patient, bevacizumab and 
triamcinolone acetonide were injected into the vitreous in an 
attempt to resolve the severe macular edema in the 
submacular area and to facilitate laser photocoagulation on 
retinal telangiectasias. This procedure has not been reported 
previously in Korea.
Case Report
A 47 year old male patient visited our hospital with the 
chief complaint ofacute progressive deterioration of the visual 
acuity of his left eye that had begun 2 months earlier. No 
specific findings were detected in his prior history. Thetotal 
cholesterol, component ratio of triglycerides, HDL-cholesterol 
and LDL-cholesterol were within the normal range. At the 
initial examination, the corrected visual acuity of his right 
and left eye was 1.0 and 0.02, respectively. The intraocular 
pressure of the right and left eye, measured using a 
non-contact tonometer, was 19 mmHg and 16 mmHg, 
respectively. The slit lamp examination revealed no specific 
special findings in the anterior segment and no rubeosis. The 
bilateral fundus examination showed normal findings in his 
right eye, and thick macular edema in the posterior pole in 
his left (Fig. 1A). Fluorescein angiography revealed profuse 
leakage with capillary dropout and a club shape thatdiffused 
to the blood vessels in the vicinity of the posterior pole (Fig. 
1B). OCT showed that the retina thickness had thickened 
noticeably to 1,187 µm as a result of macular edema (Fig. 
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Fig. 1. Pretreatment findings at initial diagnosis. (A) Color fundus photograph of the left eye at initial examination showing diffuse 
macular edema, thick hard exudates (arrow heads) and multiple vascular telangiectasias (arrows) in the temporal retina. (B) Fluorescein
angiography at initial examination shows vascular telangiectasis, areas of nonperfusion, and aneurismal dilation of retinal vessels with 
leakage of dye (small arrows). Diffuse leakage from telangiectatic vessels at major vascular arcades (large arrow). (C) Optical coherence 
tomogram shows a serous retinal detachment in the macula, and marked retinal swelling in the fovea. The retinal thickness at the central 
fovea is 1187 µm.
dilated vessel area but it was difficult to perform 
satisfactorily because of the thick retinal edema. The OCT 
taken 1 week after his first visit did not show any 
improvement of the macular edema. Therefore, bevacizumab 
(Avastin
TM, 25 mg/ml, 4 ml, Roche, USA) 1.25 mg (0.5 ml) 
was injected into the vitreal cavity in order to subside the 
retinal edema and facilitate focal laser photocoagulation on 
the telangiectatic vessels. Additional focal laser photoco- 
agulation was then performed. However, OCT taken at 3 
week visit after the injection showed that the macular 
thickness had barely changed. On the 6th week after 
treatment, an intravitreal injection of triamcinolone acetonide 
(Triamcinolone inj
®, 40 mg/ml, 5 ml, Dongkwang pharma, 
Korea) 4 mg (0.1 ml) was performed to resolve the retinal 
edema for focal laser photocoagulation. One week after the 
triamcinolone acetonide injection, the visual acuity was 0.02 
and showed no improvement. However, there was a 
noticeable reabsorption of the macular edema. At the 2
nd 
week after the injection, the foveal structures began to 
recover. After 5 weeks, the retinal thickness had decreased 
to 244 µm (Fig. 2C). The visual acuity improved slightly to 
0.04, and additional focal laser photocoagulation could be 
performed easily and satisfactorily with the absorption of the 
retinal edema. Repeated focal laser photocoagulation was 
performed at each visit until 10 weeks after injection, and the 
retinal edema remained stable. At 6 months, the OCT showed 
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Fig. 2. Posttreatment findings. (A) At 6 weeks after triam-cinolone injection, macular edema recurred slightly, but thick hard exudates 
have been absorbed nearly totally at posterior pole (large arrows). focal laser photocoagulation scars were seen at temporal side of 
posterior pole (small arrows). And they are appropriate and sufficient. (B) Fluorescein angiography at 6 months after intravitreal 
triamcinolone injection, clinically significant macular edema was still remaining but leakage from telangiectatic vessels was much 
decreased, compared with angiography at initial diagnosis (large arrow). (C) 5th week after the intravitreal triamcinolone acetonide 
injection optical coherence tomogram shows decreased macular thickness and the reabsorption of serous retinal detachment. The retinal 
thickness at the central fovea is 244 µm. (D) At 6 months, the OCT showed that the macular edema had increased to 680 µm.
that the macular edema had increased to 680 µm (Fig. 2D). 
However, on color fundus photography, thick circinate hard 
exudates was much absorbed (Fig. 2A) and, fluorescein 
angiography revealed a significant decrease in leakage from 
telangiectactic vessels compared with that performed at the 
time ofthe initial diagnosis (Fig. 2B). Consequently, repeated 
injection of triamcinolone acetonide and repeated aggressive 
laser photocoagulation was planned in order to prevent 
further progression.
Discussion
Coats’ disease develops primarily in young children under 
the age of 5 years with relatively few reports of adult cases. 
According to several studies, the progression of Coats’ 
disease is relatively slow in older children or adults, and it 
shows indolent clinical features.
1-5 In adult cases, themean 
age at the time of diagnosis is approximately 50 years with 
a male preponderance.
1 In the laboratory examination, 
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hyperlipidemia is frequently encountered as an accompanying 
condition. However, in this case, the lipid profile was 
withinthe normal range. Similar to children, the fundus 
examination shows arteriovenous dilation of the non- 
perfusion area of the capillary beds as well as subretinal lipid 
exudate andmacular edema in the vicinity. Moreover, the 
involved blood vessel area is closer to the macular area than 
that observed in typical Coats’ disease. In addition, there is 
less lipid exudate, and the retinal hemorrhage can be 
observed more often in the vicinity of the greatly dilated 
blood vessels.
1,5
The treatment and prognosis of Coats’ disease are 
influenced by the submacular exudates and the extent of 
retinal detachment. Focal laser photocoagulation or 
cryotherapy to the dilated blood vessels is the primary 
treatment for cases without exudative retinal detachment or 
mild. Drainage of the subretinal fluid, scleral buckling, pars 
plana vitrectomy can be applied in cases with severe 
exudative retinal detachment.
2, 6-8 However, in Coats’ patients, 
the application of focal laser photocoagulation to the leakage 
area is limited in most cases due to the profuse retinal edema 
caused by leakage over a wide area. Moreover, the retinal 
detachment may persist despite surgical treatments in some 
cases with extravascular fluid pooling in the outer layers over 
a wide area. Therefore, several treatment strategies have been 
attempted. Sun et al.
9 reported a case of a stage 4 pediatric 
patient who was unresponsive to scleral buckling and SRF 
drainage. The patient was treated with an intravitreal injection 
of anti-VEGF. After injecting the anti-VEGF agent, pegaptanib 
sodium, the elevated VEGF levels haddecreased markedly 
and the exudative retinal detachment had improved. However, 
in our case, there was no improvement of the exudative 
lesion after the intravitreal bevacizumab injection. Such a 
result was obtained because the exudative retinal detachment 
in Sun’s case was the increase in vascular permeability 
caused by the secondarily elevated VEGF due to retinal 
ischemia. Our case it was Stage 2A according to the Shields 
classification. In addition, the ischemic area was not wide 
and there was only a slight increase in level of VEGF. 
Therefore, it is not surprising that no noticeable improvement 
was observed after the bevacizumab injection. This means 
that the increase in vascular permeability in Coats’ disease 
is induced primarily by morphological problems, and an 
elevated VEGF level could increase the permeability 
secondarily with the progression of the disease due to 
advanced retinal ischemia. Consequently, the therapeutic 
reaction differs according to the change in pathophysiology 
during disease progression. 
Jarin et al.
10 reported that an intravitreal injection of 
triamcinolone acetonide was effective in an adult Coats’ 
patient who was unresponsive to conventional laser photo- 
coagulation due to the presence of severe macular edema. 
The microcirculation of the retinal blood vessels and edema 
were stabilized by triamcinolone because it has been shown 
to be effective against microangiopathy of which Coats’ 
disease is a chronic form.
11 However, in previous report, 
Jonas et al.
12 reported two patient with Coats’ like features 
that was unresponsive to intravitreal traimcinolone. The 
results of our case are similar to Jarin’s case. Moreover, in 
Coats’ disease, macular edema develops as a result of leakage 
due to destruction of the blood-retinal barrier through the loss 
of vascular endothelial cells and adjacent cells induced by 
causes yet to be determined. Hence, in addition to VEGF, 
other cytokines are believed to be involved. Therefore, it is 
believed that triamcinolone acetonide injected into the the 
intravitreal cavity suppressed a variety of cytokines and 
induced some short term improvement in macular edema. 
Overall, Coats’ disease with severe retinal edema can be 
treated accurately and satisfactorily by laser photoaco- 
agulation on the targeted leakage area after absorbing the 
retinal edema through a triamcinolone acetonideinjection. In 
addition, it is believed that the partial retinal edema that 
remained after photocoagulation can be improved with an 
intravitreal injection of triamcinolone acetonide. However, 
statistical analysis of the effectiveness of the adjunct 
treatment based on a larger number of cases will be needed.
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